Form 4: Gilead Sciences Chief Medical Officer Executes Stock Transactions

Gilead Sciences' Chief Medical Officer, Merdad Parsey, engaged in multiple stock option exercises and sales on November 27, 2024.

Summary

• Merdad Parsey, Chief Medical Officer of Gilead Sciences, executed several transactions involving the company's stock on November 27, 2024.
• These transactions included the exercise of stock options to acquire 57,294 shares at $57.92 and 88,119 shares at $65.38.
• Following the option exercises, Mr. Parsey sold 57,294 shares at an average price of $91.7949, 88,119 shares at $92, 5,200 shares at an average price of $91.8041, 3,199 shares at an average price of $91.8034, and 10,399 shares at $92.
• The total number of shares owned by Mr. Parsey after these transactions is 80,801.
• The stock options exercised have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining balance vesting quarterly thereafter.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It's a neutral event.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry. These transactions are often part of executive compensation packages and are closely monitored by investors.

Comparison to Industry Standards

• Stock option exercises and sales are a standard part of executive compensation in the pharmaceutical industry, similar to practices at companies like Amgen (AMGN) and Regeneron (REGN).
• The vesting schedule of the options, with a four-year period and quarterly vesting after the first year, is also typical for executive stock options.
• The sale of shares after exercising options is a common practice for executives to realize the value of their compensation.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the volume of shares sold, but this is likely to be minimal given the overall trading volume of Gilead stock.
• Shareholders will be interested in the details of executive compensation and stock transactions.

Key Dates

Keywords

Gilead Sciences, stock options, stock sale, Merdad Parsey, insider trading, executive compensation, GILD